Clinical Trials

CONTRAST-NP: Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lebrikizumab/LY3650150 in Participants with Chronic Rhinosinusitis with Nasal Polyps on Background Intranasal Corticosteroids

• Ideal for adult participants ≥18 years and adolescent participants ≥12 to <18 years of age and weighing ≥40kg at Visit 1 with physician-diagnosed CRS with bilateral nasal polyps